|

RMC-6291 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Revolution Medicines, Inc.1

Indications

  • RAS G12D-mutated NSCLC1
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer1
  • KRAS G12C-mutated Solid Tumors, Lung Cancer1
  • KRAS, NRAS, HRAS-mutated NSCLC1
  • Non-small Cell Lung Cancer (NSCLC)1

Gilbert, Arizona1 trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Banner MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.